← All Nrx Pharmaceuticals, INC filings

Nrx Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
NRXP
Nrx Pharmaceuticals, INC
10-K: NRx Pharmaceuticals Advances Drug Pipeline, Expands HOPE Network Amidst Going Concern Warning
NRx Pharmaceuticals reports significant progress in its neuroplasticity drug pipeline and the expansion of its interventional psychiatry subsidiary, HOPE Therapeutics, despite facing substantial financial losses and a going concern warning.
NASDAQ
NRXP
Nrx Pharmaceuticals, INC
10-K/A: NRx Pharmaceuticals Files Amendment to 10-K Report, Providing Updated Information on Directors, Executive Compensation, and Corporate Governance
NRx Pharmaceuticals files an amendment to its 2024 annual report on Form 10-K to update information regarding directors, executive compensation, security ownership, related transactions, and accounting fees.
NASDAQ
NRXP
Nrx Pharmaceuticals, INC
10-K: NRx Pharmaceuticals Reports Fiscal Year 2024 Results, Highlights Progress in Drug Development and Strategic Initiatives
NRx Pharmaceuticals details its financial results for fiscal year 2024, emphasizing advancements in its drug pipeline and strategic shift towards revenue generation through HOPE Therapeutics.
NASDAQ
NRXP
Nrx Pharmaceuticals, INC
10-K/A: NRx Pharmaceuticals Files Amended 10-K Report, Providing Updated Information on Directors, Compensation, and Governance
NRx Pharmaceuticals has filed an amendment to its annual report on Form 10-K to include information required by Part III, Items 10-14, and Part IV, Item 15, of the original filing.
NASDAQ
NRXP
Nrx Pharmaceuticals, INC
10-K: NRx Pharmaceuticals Outlines Strategic Growth and Financial Restructuring in 10-K Filing
NRx Pharmaceuticals' 10-K filing details a year of significant growth, strategic partnerships, and financial restructuring, positioning the company for future expansion.